Headache News and Research

Latest Headache News and Research

Children more likely to pick up stomach infections from private water supplies

Children drinking from around half the UK's private water supplies are almost five times more likely to pick up stomach infections - according to research from the University of East Anglia (UEA).

26 Aug 2012

Guidelines for parents to beat back-to-school bugs

School bells are beginning to sound again across the country, so it will only be a matter of time until every parent comes face-to-face with a child who wakes up with a cold, fever or upset stomach.

24 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

Healthcare announces important changes to the U.S. product label for Optison

GE Healthcare today announced important changes to the U.S. product label for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.

22 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

CDC reports worst West Nile virus outbreak in the U.S.

This past year's mild winter and wet spring could be contributing to the worst West Nile virus outbreak since the disease was first detected in the United States in 1999. According to the Centers for Disease Control and Prevention, there have been more cases of the virus so far this year than any year. As of August 14, almost 700 cases had been reported across the nation, including 26 deaths. This year also marks the earliest reported case of West Nile virus in New Jersey.

18 Aug 2012

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.

18 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Mepolizumab almost halves exacerbations in severe asthma patients

The largest study of patients with severe asthma to date, published in The Lancet special issue on respiratory medicine, shows that those treated with the monoclonal antibody mepolizumab experienced an almost 50% reduction in severe exacerbations, emergency room visits, and hospitalisations compared with patients given placebo.

17 Aug 2012

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

Taking oral contraceptives continuously, rather than as traditionally prescribed for each cycle, provides earlier relief for moderate to severe menstrual cramps -- dysmenorrhea -- according to researchers at Penn State College of Medicine.

16 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Risk of arteriovenous malformation bleeding is eight times higher during pregnancy

A new study supports what neurosurgeons have long suspected—that pregnancy is an important risk factor for bleeding from arteriovenous malformations (AVMs) in the brain, reports the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

8 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

Cerebrospinal fluid analysis is only necessary for patients with thunderclap headache and a negative computed tomography scan if they undergo imaging more than 6 hours after headache onset, research suggests.

6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

Headache News and Research

Latest Headache News and Research

Children more likely to pick up stomach infections from private water supplies

Guidelines for parents to beat back-to-school bugs

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Healthcare announces important changes to the U.S. product label for Optison

Enzalutamide extends castration-resistant prostate cancer survival

CDC reports worst West Nile virus outbreak in the U.S.

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Mepolizumab almost halves exacerbations in severe asthma patients

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

FDA approves Intelliject's Auvi-Q for anaphylaxis

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Risk of arteriovenous malformation bleeding is eight times higher during pregnancy

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Headache News and Research

Latest Headache News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in